Page 244 - Drug Class Review
P. 244
Page 152 of 205
Drug Effectiveness Review Project
placebo 74.2 59 NR 18.7 26.9 Secondary Outcome Measures: CGIC; PDS-1 (quality of life measure) No significant differences in PDS-1 score for any dose of GAL compared to placebo (ITT) GAL 24 mg/d produced greater improvement in ADAS-Cog change compared to placebo (P = 0.01); mean change from baseline for GAL 18 mg/d and GAL 32 mg/d not statistically different No significant differences in CGIC for any dose of GAL compared to placebo (ITT)
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes
72.7; 72.9; 75.4 galantamine 18; 24; 36 mg/d 56; 59; 57 NR 18.8, 18.2, 18.8 26.0, 26.7, 25.7 Primary Outcome Measures: ADAS-Cog Timing of assessments: Baseline and weeks 6 and 12 Health Outcome Measures: Intermediate Outcome Measures: from placebo
• • •
Final Report Update 1 Authors: Wilkinson et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Baseline MMSE • Baseline ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
